Status:
ACTIVE_NOT_RECRUITING
Impact of Lp299v on Vascular Function in Patients With PASC
Lead Sponsor:
Medical College of Wisconsin
Conditions:
COVID-19
Eligibility:
All Genders
18-89 years
Phase:
NA
Brief Summary
Emerging data show that SARS-CoV-2 infection causes gut microbiome changes strongly associated with Post-Acute Sequelae of SARS-CoV-2 (PASC). The investigators and others have established that an oral...
Detailed Description
The intestinal immune system plays a critical role in systemic immunity, and its interaction with the systemic immune system plays a crucial role in determining the severity and outcomes of common pul...
Eligibility Criteria
Inclusion
- Ages 18 to 89 years
- 30-180 days post-COVID-19 diagnosis
- PASC diagnosed based on symptom report/expert physician judgement
Exclusion
- Antibiotics within four weeks of enrollment
- History of chronic diseases (renal insufficiency, liver dysfunction, cancer requiring systemic treatment within 3 years of enrollment)
- History of cognitive impairment/inability to follow study procedures
- Short gut syndrome, inflammatory bowel disease, or an ileostomy.
- Subjects currently taking Vitamin K antagonists such as coumadin or warfarin
- Pregnant at the time of screening
- Unstable coronary artery disease (new symptoms or event within 30 days of enrollment)
- Daily alcohol use (may interfere with Lp299v's action)
Key Trial Info
Start Date :
April 29 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 31 2026
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT05227170
Start Date
April 29 2022
End Date
March 31 2026
Last Update
April 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical College of Wisconsin
Milwaukee, Wisconsin, United States, 53226